Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers

https://doi.org/10.17749/2070-4909.2019.12.2.65-71

Full Text:

Abstract

Aim: to assess the socio-economic burden of smoking in the Russian Federation for 2017.

Materials and methods. The socio-economic burden was calculated and extrapolated to the entire population of smokers in Russia and then compared with equal sized populations of quitters and non-smokers.

Results. In 2017, the burden of tobacco smoking (including the direct costs of medical care and payment for temporary disability, as well as indirect costs - the under-received gross domestic product (GDP) due to temporary disability) was 510.6 billion rubles. The difference between the smokers and the equal-sized non-smoking population is 327.6 billion rubles. The difference between the smokers and the equalsized population of quitters was 216.1 billion rubles.

Conclusion. Costs associated with smoking are sizable. Helping quit tobacco smoking (government anti-smoking measures, pharmacotherapy etc.) will not only improve the quality of life and health expectancy of smokers but also save a considerable amount of budget funds.

About the Authors

E. V. Radchenko
Pavlov First Saint Petersburg State Medical University
Russian Federation

Elena V. Radchenko - MD, PhD Student, Department of Clinical Pharmacology and Evidence-based Medicine.

6-8 L’va Tolstogo Str., Saint Petersburg 197022



A. S. Kolbin
Pavlov First Saint Petersburg State Medical University
Russian Federation

Aleksei S. Kolbin - MD, PhD, Professor, Head of the Department of Clinical Pharmacology and Evidence-based Medicine, Pavlov SMU; Professor, Department of Pharmacology, Saint-Petersburg SU; President of the St. Petersburg branch of ISPOR (International Society for Pharmacoeconomic Research and Scientific Analysis of Outcomes).

6-8 L’va Tolstogo Str., Saint Petersburg 197022



References

1. Forouzanfar M. H. et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016; 388 (10053): 1659-1724.

2. Jha P. et al. 21st-century hazards of smoking and benefits of cessation in the United States. New England Journal of Medicine. 2013; 368 (4): 341-350.

3. Ekpu V.U., Brown A.K. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence. Tobacco Use Insights. 2015; (8): 1-35. DOI: https://doi.org/10.4137/TUI.S15628.

4. Reitsma M. B. et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. The Lancet. 2017; 389 (10082): 1885-1906.

5. Sakharova G. M., Antonov N. S., Salagai O. O. Global Adult Survey on Tobacco Use in the Russian Federation: GATS 2009 and GATS 2016. Narkologiya. 2017; 16 (7): 8-12. URL: http://www.narkotiki.ru/50_2329.htm.

6. Global Adult Tobacco Survey 2016 (in Russ.) [Electronic resource]. URL: https://www.who.int/tobacco/surveillance/survey/gats/gats_2016-rus-executive-summary-Ru.pdf?ua=1. Accessed: 21.02.2019.

7. Thun M.J., Apicella L.F., Henley S.J. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA. 2000; 6 (284): 706-712. DOI: https://doi.org/10.1001/jama.284.6.706.

8. The official site of the Territorial Fund of the OMS of St. Petersburg. OMS General Tariff Agreement for 2018. Sankt-Peterburg. (in Russ.) [Electronic resource]. URL: https://spboms.ru. Accessed: 20.12.2018.

9. Federal State Statistics Service (in Russ.) [Electronic resource]. URL: http://www.gks.ru. Accessed: 07.01.2019.

10. Ignatyeva V.I., Avxentyeva M.V. The analysis of methodologic characteristics of researches on social and economic burden of diseases in Russia in the frames of development of standard cost of illness methodology for the health technology assessment. FARMAKOEKONO-MIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. (in Russ.) 2014; 7 (3): 3-11. (In Russ.)

11. Single E., Robson L., Rehm J. et al. Morbidity and mortality attributable to alcohol, tobacco, and illicit drug use in Canada. American Journal of Public Health. 1999; 3 (89): 385-390. DOI: https://doi.org/10.2105/ajph.89.3.385.

12. Yagudina R.I., Skripnik A.R. Comparative economic modeling of the effects of smoking from the Russian Federation (from 2009 to 2016). Farmakoekonomika: teoriya i praktika. (in Russ.) 2018; 6 (2): 31-37. DOI: https://doi.org/10.30809/phe.2.2018.5.


For citation:


Radchenko E.V., Kolbin A.S. Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2019;12(2):65-71. (In Russ.) https://doi.org/10.17749/2070-4909.2019.12.2.65-71

Views: 158


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)